Outcomes of ILUVIEN (fluocinolone acetonide intravitreal implant 0.19mg) for Non-Infectious Uveitis (NIU): A Retrospective Case-Series

Navnoor Singh, Aprajita Sinha, Devika Nair, Salman Mirza


Worcestershire Acute Hospitals NHS Trust

Introduction/Aim

- NIU remains a challenge to treat as delivery of the therapeutic drug dose to the posterior segment essential
- 2019 NICE guidelines recommend the use of a fluocinolone implant for NIU
- Aim – to assess outcomes and complications of ILUVIEN at 12 months

Methods

- Patient records from 2020-2022 analysed
- Data from pre-injection and 12-months post injection collected including:
  - Best corrected visual logMar acuity
  - Central retinal thickness
  - Severity of vitreous inflammation (NIH classification for vitreous haze)
  - Complications
- Final outcomes classified as:
  - Success:quiescent or controlled
  - Qualified success:limited control or reduced treatment
  - Failure: Severe complication/worsening inflammation




Underlying Cause of NIU	n (total = 78)
Birdshot chorioretinopathy	6
HLA B27 related uveitis	2
Idiopathic	48
Multiple sclerosis	1
Psoriasis	2
Sarcoidosis	18
Sympathetic ophthalmitis	1

Results

- A total of 78 eyes in 63 patients included with mean age 54.9 years (22-86
- years)

  12-month follow-up data (at least one metric) available on 69/78 eyes
- Macular edema reduced from 30% at baseline to 8.9% at 12-month follow-up
- Most patients had decreased vitreous haze
- Mean increase in IOP at 12 months was 1mm of Hg
- 87% (60/69) eyes qualified as success or qualified success

Parameter (mean)	Baseline (n)	12-month post ILUVIEN (n)	p (2-tailed t-test)
BCVA (LogMar)	0.297 (75)	0.240 (63)	0.24
CRT (microns)	404.83 (30)	336.71 (28)	0.02



Complications

- 8/38 (21%) phakic eyes with no cataract developed cataract.
- 2/17 (11.7%) eyes with prior cataract had worsening of cataract.
- 4/55 (7.27%) phakic eyes had cataract surgery
- 7 eyes (10.1%) required IOP lowering procedures
- 9/69 (13%) eyes classified as failures

Conclusions

- ILUVIEN is an effective treatment for NIU
- Results in significant reduction in CRT(p 0.02)
- Improved visual acuity
- Adverse effects of ocular hypertension/glaucoma and cataract